Fernando Gamarra (Straubing, Germany), Ross Morgan (Dublin, Ireland), Georgia Hardavella (London, United Kingdom), Chi-Leung David Lam (Hong Kong SAR, Hong Kong)
Preoperative cell counts of white blood cell, neutrophil, lymphocyte and neutrophil/lymphocyte ratio as a predictive parameter of survival rate after complete resection for non-small cell lung cancer
Jae Joon Hwang (Seoul, Republic of Korea), Jae Joon Hwang, Cheon Woong Choi, Jee-Hong Yoo, Dae Hyun Kim, Hong Mo Kang, Myung Jae Park
|  |
Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy
Shinichiro Ryuge (Kanagawa, Japan), Shinichiro Ryuge, Yuichi Sato, Ken Katono, Ryo Nagashio, Masanori Yokoba, Masato Katagiri, Kazu Shiomi, Yukitoshi Satoh, Noriyuki Masuda
|  |
Expression and clinical implications of the estrogen receptor β in lung adenocarcinoma
Nensi Lalić (Sremska Kamenica, Republic of Serbia), Nensi Lalic, Branislav Perin, Zdravko Kosjerina, Milana Panjkovic
| |
Locally advanced stage nonsmallcell cancers explode in hyperglisemia: A new prognostic factors?
Berna Kömürcüoğlu (Izmir, Turkey), Berna Kömürcüoglu, Esra Korkmaz, Cenk Kirakli, Bilge Salik
| |
Prevalence of mutations in Romanian patients with non-squamous lung carcinoma evaluated through next generation sequencing
Tudor Andrei Cernomaz (Iasi, Romania), Tudor Andrei Cernomaz, Ina Iuliana Macovei, Ionut Pavel, Carmen Grigoriu, Mihai Marinca, Simona Peter, Radu Zonda, Madalina Lavinia Berlea, Florin Rusu-Cordunean, Bogdan-Dragos Grigoriu
| |
Potential lung cancer biomarkers from bronchoalveolar lavage fluid using metabolomics approaches
Victoria Ignacio Barrios (Ronda, Spain), Victoria Ignacio Barrios, Belén Callejón Leblic, Tamara García Barrera, Jesús Grávalos Guzmán, Pilar Muñoz Zara
| |
The effect of surgical specimen-derived phosphorus and lead concentrations in non-small cell lung cancer patients on disease course
Elif Yilmazel Uçar (Erzurum, Turkey), Ömer Araz, Asli Araz, Elif Yilmazel Uçar, Elif Demirci, Metin Akgün, Leyla Saglam
| |
Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) as a possible biomarker for lung cancer and/or COPD
Angeliki Loukeri (Nikea, Greece), Angeliki Loukeri, Panagiotis-Dimitrios Spithakis, Charalampos Moschos, Pinelopi Loukeri, Anastasia Bartzeliotou, Aikaterini Tzagkaraki, Eustratios Stratos, Dimitrios Veldekis, Christos F. Kampolis
| |
Correlation of bim and noxa expression with clinicopathological features in NSCLC
Eleftheria Chaini (Corfu, Greece), Eleftheria Chaini, Anna Maria Athanassiadou, Angelos Tsipis, Kyriakos Hainis, Maria Gonidi, Pauline Athanassiadou
| |
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Roberto Chalela (Barcelona, Spain), Roberto Chalela, Beatriz Bellosillo, Víctor Curull, Lara Pijuan, Joaquín Gea
| |
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Dora Marinova (Sofia, Bulgaria), Dora Marinova, Darina Kachakova, Atanaska Mitkova, Gergana Stancheva, Yanina Slavova, Denitsa Dimitrova, Evgeni Mekov, Aleksandar Lilov, Miroslav Mihailov, Dimitar Kostadinov, Radka Kaneva, Vanio Mitev
| |
The role of HIF-1 pathway in non-small-cell lung cancer
Ercan Kurtipek (Konya, Turkey), Ercan Kurtipek, Nadir Koçak, Hidir Esme, Nuri Düzgün, Süleyman Emre Akin, Yasar Ünlü, Taha Tahir Bekçi
| |
Association of the endothelin-1 and endothelin A receptor genetic polymorphisms and non-small cell lung cancer in Taiwan
Chuen-Ming Shih (Taichung, Taiwan), Yao-Ling Lee, Chuen-Ming Shih
| |
Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Mesut Bayraktaroglu (Istanul, Turkey), Engin Aynaci, Funda Seçik, Ender Coskunpinar, Mesut Bayraktaroglu, Didem Görgün, Pinar Yildiz
| |
NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations
Jorge Moisés Lafuente (Barcelona, Spain), Jorge Moisés Lafuente, Sandra Santasusagna, Alfons Navarro, Nuria Viñolas, Josep Ramirez, Laureano Molins, Carlos Agustí, Jeisson Osorio, Adela Saco, Marc Ruiz, Joan Castellano, Anna Cordeiro, Carmen Muñoz, Mariano Monzo, Ramón Marrades
| |
Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Giovanni Ferrara (Stockholm, Sweden), Elsa Davisdsson, Nicola Murgia, Cristian Ortiz-Villalon, Emil Wiklundh, Magnus Sköld, Karl Kölbeck, Giovanni Ferrara
| |
Serum hepcidin and iron are associated with non-small cell lung cancer stage
Kento Sato (Yamagata, Japan), Kento Sato, Yoko Shibata, Sumito Inoue, Akirai Igarash, Yoshikane Tokairin, Keiko Yamauchi, Tomomi Kimura, Takako Nemoto, Masamichi Sato, Hiroshi Nakano, Yuki Abe, Isao Kubota
| |
Prognostic implications of smoking in patients with advanced lung adenocarcinoma excluding positive mutations
Tomohiro Kato (Himeji, Japan), Tomohiro Kato, Yasuharu Nakahara, Katsuya Hirano, Ryota Kominami, Yasutaka Onishika, Yasushi Fukuda, Ryogo Kagami, Runko Katsuda, Kenji Hanaoka, Yoko Yokoi, Kouhei Miyake, Yasuyuki Mizumori, Hiroaki Tsukamoto, Shin Sasaki, Tetsuji Kawamura, Yoshiro Mochizuki
| |
CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation
Nuo Xu (Shanghai, China), Nuo Xu, Fanglei Liu, Jian Zhou, Chunxue Bai
| |
Prognostic significance of the expressions of Axl and/or Gas6 in patients with completely resected lung adenocarcinoma
Cheol-Hong Kim (Gyeonggi-do, Republic of Korea), Cheol-Hong Kim, Dong-Gyu Kim, In-Gyu Hyun, Masahiro Seike
| |